Skip to main content
. Author manuscript; available in PMC: 2007 Nov 28.
Published in final edited form as: Bone Marrow Transplant. 2005 Nov;36(9):771–779. doi: 10.1038/sj.bmt.1705138

Table II.

Haematological recovery and toxicity in the three groups of patients (i.e., anti-IL-6, DEX and HDM140, HDM140 and HDM200).

graphic file with name halms136072f9.jpg

HDM= High dose melphalan

1

Patients having anti-IL-6 mAb before high dose melphalan were hospitalized 4 additional days because of a Phase II protocol, avoiding any clinical problem.